Uterine Carcinosarcoma
22
1
3
14
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
15 trials with published results (68%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
13.6%
3 terminated out of 22 trials
82.4%
-4.2% vs benchmark
5%
1 trials in Phase 3/4
107%
15 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 14 completed trials
Clinical Trials (22)
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer